Legend Biotech CARVYKTI® Sales Hit $286M
Ticker: LEGN · Form: 6-K · Filed: Oct 15, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $286 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: sales-update, pharmaceutical, collaboration
TL;DR
Legend Biotech's CARVYKTI® pulled in $286M last quarter, good news for the stock.
AI Summary
Legend Biotech Corporation announced on October 15, 2024, that CARVYKTI® generated approximately $286 million in net trade sales for the quarter ended September 30, 2024. This figure is based on information provided by Janssen Biotech, Inc., under their December 21, 2017, Collaboration and License Agreement.
Why It Matters
This preliminary sales figure for CARVYKTI® provides investors with an early look at the drug's commercial performance, impacting Legend Biotech's revenue expectations.
Risk Assessment
Risk Level: low — This is a routine sales update, not a major strategic shift or financial distress.
Key Numbers
- $286 million — CARVYKTI® Net Trade Sales (Preliminary sales for the quarter ended September 30, 2024.)
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- CARVYKTI® (product) — Drug generating sales
- $286 million (dollar_amount) — Net trade sales for Q3 2024
- September 30, 2024 (date) — End of reporting quarter
- October 15, 2024 (date) — Date of announcement
- Janssen Biotech, Inc. (company) — Collaboration partner
- December 21, 2017 (date) — Date of Collaboration and License Agreement
FAQ
What is the total net trade sales for CARVYKTI® for the quarter ended September 30, 2024?
Legend Biotech announced that CARVYKTI® generated approximately $286 million in net trade sales for the quarter ended September 30, 2024.
Who is Legend Biotech's partner for CARVYKTI®?
Legend Biotech's partner for CARVYKTI® is Janssen Biotech, Inc., under a Collaboration and License Agreement dated December 21, 2017.
When was this sales information announced?
This sales information was announced on October 15, 2024.
What type of filing is this report?
This report is a Form 6-K, a Report of Foreign Private Issuer.
What is the principal executive office address for Legend Biotech?
The principal executive office address for Legend Biotech is 2101 Cottontail Lane, Somerset, New Jersey 08873.
Filing Stats: 728 words · 3 min read · ~2 pages · Grade level 18.7 · Accepted 2024-10-15 07:30:43
Key Financial Figures
- $286 million — CARVYKTI ® generated approximately $286 million in net trade sales during the quarter e
Filing Documents
- f6k_101524.htm (6-K) — 12KB
- 0001171843-24-005616.txt ( ) — 13KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: October 15, 2024 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer